reports
Supernus Pharmaceuticals to Participate in September Investor Conferen...
Supernus Pharmaceuticals to Participate in September Investor Conferences ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Fireside chat:Place: Wednesday, September 3, 2025 8:00 a.m. ET New York Marriott Marquis, New York, NY Wells Fargo Healthcare ConferenceDate:Firesid...
Supernus Announces Second Quarter 2025 Financial Results
Supernus Announces Second Quarter 2025 Financial Results Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 m...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage”...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Wai...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025. On Ju...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Res...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice Presi...
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening i...
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent valu...
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relatio...
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awarenes...
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
Supernus Announces Paragraph IV ANDA Filings for Qelbree® ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details o...
Supernus to Participate in the 2025 Jefferies Global Healthcare Confer...
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting with...
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresent...
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more often seen in malesBoys are two times more likely to be diagnosed with ADHD than girls, leaving many girls and women undiagnosed and untreatedBusy is flipping the script for women with ADHD by sharing her own diagnosis and treatment journey with Qelbree® (viloxazine extended-release...
Supernus Announces First Quarter 2025 Financial Results
Supernus Announces First Quarter 2025 Financial Results First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to oper...
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Resu...
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President an...
Supernus to Participate in Two Upcoming Investor Conferences
Supernus to Participate in Two Upcoming Investor Conferences ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare ConferenceDate: Tuesday, March 11, 2025Fireside chat: 12:30 p.m. ETPlace: Loews Miami Beach Hotel, Miami, Fla. Jefferies Bi...
Supernus to Participate in the TD Cowen 45th Annual Health Care Confer...
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Investors interested in arranging a meeting with co...
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023.Fourth quarter 2024 net sales of GOCOVRI® increased 15% to $36.9 million, compared to the same period in 2023. Full year net sales of GOCOVRI increased 9% to $130.8 million, compared to full year 2023.Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total reve...
Supernus Announces Topline Results from Phase 2b Study in Adults with ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated with few adverse events, consistent with previously reported studies ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS...
Supernus Pharmaceuticals to Host Conference Call and Webcast on Februa...
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. Jack Khattar, President and CE...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride)...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025 ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on deve...
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelb...
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamicsQelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies1 ROCKVILLE, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,...
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Co...
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City. Inves...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.